Biphasic or Mixed
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read MoreAnalysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
Oncology 2025 January 24 [Link] Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM)…
Read MoreReal-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study
Asia-Pacific Journal of Clinical Oncology 2024 December [Link] Kar Ven Cavan Chow, Cassie Turner, Brett Hughes, Zarnie Lwin, Bryan Chan Abstract Aim: To evaluate the real-world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy. Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers…
Read MoreVolatile Organic Compound Analysis of Malignant Pleural Mesothelioma Chorioallantoic Membrane Xenografts
Journal of Breath Research 2024 August 20 [Link] Liam David Little, Sarah E Barnett, Theo Issitt, Sam Bonsall, Vikki Amanda Carolan, K Elizabeth Allen, Laura Margaret Cole, Neil A Cross, Judy M Coulson, Sarah Louise Haywood-Small Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure. MPM is often diagnosed late, at…
Read MoreFK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology
Molecular Medicine 2024 May 31 [Link] James Mei-Lin Chan, Yuan-Ching Chang, Hua-Chen Chan, Hsiu-Chuan Chan, Wei-Chin Chang, Liu-Fang Wang, Tung-Hu Tsai, Yu-Jen Chen, Wen-Chien Huang Abstract Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally…
Read MorePredictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma
European Journal of Radiology 2024 May 26 [Link] Ritu R Gill, William G Richards, Hillary Heiling, Emanuele Mazzola, Yin P Hung, Ravi T Seethamraju, Lucian R Chirieac, Raphael Bueno Abstract Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreDiffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…
Read MoreMethylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma
Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…
Read MoreValidation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series
Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…
Read More